

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

Offenburg, November 3, 2020

MEDICLIN publishes forecast for fiscal year 2020

Return to normal operations is elementary for the future business performance

The ongoing gradual return to normal operations led to increasing occupancy in the clinics in the third quarter of 2020 and thus to a positive development in sales and earnings. The occupancy rate in October is also consistently above the level of the 3rd quarter of 2020 - with a slight upward trend.

Due to this development and provided that in the 4th quarter of 2020 the capacity utilization can be kept at the current level or normal operation can continue further despite a currently strong nationwide increase in the number of corona infected people, the Management Board assumes that the Group sales are around 2% below the previous year's figure and the group operating result is expected to be at the breakeven point.

Despite rising occupancy in the 3rd quarter of 2020, the effects of the coronavirus pandemic on the business performance is clearly noticeable

The spread of the corona pandemic and the challenges specifically associated with our industry had a major impact on the Group's business development in the first nine months of the 2020 financial year. In the second quarter in particular, the requirements of the federal government to reserve capacities for an increasing number of infected people as a precautionary measure made themselves felt in the Group's sales and operating result.

From mid-March to mid-June, the MEDICLIN acute clinics cancelled all deferred operations and increased ventilation capacities by 40%. As far as the post-acute clinics are concerned, more than half of the facilities had, in coordination with the respective Land governments, kept bed capacities free for corona patients or to ease the burden on the regional hospitals

Since mid-June 2020, all facilities have been gradually returning to normal operation and implementing the higher hygiene and protection regulations. The gradual start of normal operation under the new hygiene requirements is reflected in the increasing occupancy rate in the third quarter and thus in a significantly improved sales and earnings development compared to the two previous quarters.

Group sales were 1.2% below the previous year

In the first nine months of the 2020 financial year, MEDICLIN achieved consolidated sales of EUR 498.7 mill., EUR 6.0 mill. or 1.2% less than in the same period of the previous year. MEDICLIN showed a sales decline of 3.5% at the half-year mark.

The Group operating result was EUR 2.0 million (9 M 2019: EUR 14.9 mill.), the Group EBIT for the first half was EUR -8.8 mill. In addition, the Group EBIT is burdened by a one-off effect of EUR -1.5 mill. from the write-down on the book value in connection with the planned sale of the MediClin Krankenhaus am Crivitzer See GmbH, Crivitz, on December 31, 2020.

Für weitere Informationen:

MEDICLIN Aktiengesellschaft Okenstraße 27 77652 Offenburg Germany

Investor Relations Alexandra Mühr Phone +49 781/488-326 Fax +49 781/488-184 alexandra.muehr@mediclin.de

Public Relations Gabriele Eberle Phone +49 781/488-180 Fax +49 781/488-184 gabriele.eberle@mediclin.de

www.mediclin.de



Disclosure of an inside information acc. To Article 17 MAR of the Regulation (EU) No 596/2014

Different developments in the segments

In the post-acute segment, sales of EUR 292.7 mill. were EUR 20.6 million or 6.6% below the previous year's figure. The segment EBIT was EUR 0.1 million (9 M 2019: EUR 18.6 million).

Sales in the acute segment increased by EUR 16.4 mill. or 9.3% compared to the first nine months of 2019. The segment EBIT improved compared to the same period of the previous year to EUR 5.5 mill. (9 M 2019: EUR -1.5 mill.).

Investment pace slowed

In the first nine months of the 2020 financial year, EUR 20.5 mill. (gross) were invested (9 M 2019: EUR 34.9 mill.). As a precautionary measure, the investments are below the annual plan for liquidity reasons. As of September 30, 2020, cash and cash equivalents amounted to EUR 88.6 mill. (December 31, 2019: EUR 37.2 mill.). The liquid funds on the reporting date include subsidies for the construction of a new clinic and, as a precaution, reimbursement claims from the Corona protective shield.

The interim report as of September 30, 2020 is available from today at www.mediclin.de in German and English.

Key figures - yoy comparison of the Group and the segments

| in million € | 9M 2020 | 9M 2019 |
|--|---------|---------|
| Group | | |
| Group sales | 498.7 | 504.7 |
| Raw materials and consumables used | 85.5 | 91.2 |
| Staff costs | 319.3 | 308.7 |
| Depreciation and amortisation | 58.6 | 53.0 |
| Other operating expenses | 41.1 | 43.7 |
| Group operating result | 2.0 | 14.9 |
| Total consolidated result | -4.4 | 5.8 |
| Cash flow from operative activities | 96.2 | 54.5 |
| Earnings per share in € (un-/diluted) | -0.09 | 0.12 |
| Number of employees (full time staff on average) | 7,480 | 7,383 |

Post-acute

| Sales | 292.7 | 313.3 |
|-------------------------------------|-------|-------|
| Segment result | 0.1 | 18.6 |
| Acute | | |
| Sales | 192.8 | 176.4 |
| Segment result | 5.5 | -1.5 |
| Other activities and reconciliation | | |
| Sales | 13.2 | 15.0 |
| thereof business area nursing care | 11.8 | 11.5 |
| Segment result | -3.6 | -2.2 |

(Due to arithmetical reasons, calculation differences may occur in the table above)

About MEDICLIN AG (Ticker: MED; WKN: 659 510)

MEDICLIN owns 36 clinics, seven nursing care facilities and nine medical care centres. The Group has about 8,500 beds/places and a headcount of about 10,500. With its strong network, MEDICLIN can offer its patients integrated care from the first visit to the doctor to surgery, post-operative rehabilitation and follow-up care at home. Doc-tors, therapists and nurses work together closely to achieve the best results. MEDICLIN plans the care of persons in need in accordance with their individual requirements and personal needs.

MEDICLIN – A company of the Asklepios Group.